PetCaseFinder

Peer-reviewed veterinary case report

Survival rates for cats with oral cancer in the UK

By Hayes, A M et al.·Published in The Journal of small animal practice·2007·Centre for Small Animal Studies, United Kingdom·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Survival of 54 cats with oral squamous cell carcinoma in United Kingdom general practice.

Species:
cat

Plain-English summary

A group of 54 cats diagnosed with oral squamous cell carcinoma (a type of mouth cancer) were treated in veterinary practices across the UK. On average, these cats survived about 44 days after diagnosis, with only 9.5% living for a year. Cats that were pedigree or received non-steroidal anti-inflammatory drugs (NSAIDs) after diagnosis had better survival rates. While the prognosis for this cancer is generally poor, using palliative treatments like NSAIDs may help cats live longer and feel more comfortable.

People also search for: cat mouth cancer survival · feline oral squamous cell carcinoma treatment · NSAIDs for cats with cancer

Abstract

OBJECTIVES: To determine the survival of 54 cats with histologically confirmed feline oral squamous cell carcinoma (FOSCC) treated in UK general practice and to determine factors predictive for survival. METHODS: Cases were identified from consecutive samples submitted for histological diagnosis. Observational and survival data were collated retrospectively from submitting practices. Immunohistochemical analysis of cyclooxygenase (COX) expression variables was available using previously published data. Kaplan-Meier product limit estimation for overall survival and Cox proportional hazards regression for potential explanatory variables were performed. RESULTS: The overall median survival time was 44 days [95 per cent confidence interval (CI): 31-79] and 1 year survival was 9.5 per cent. Variables associated with survival were whether the cat was pedigree [hazard ratio (HR)=8.17, 95 per cent CI: 1.96-34.12], whether the cat received non-steroidal anti-inflammatory drug (NSAID) therapy after diagnosis (HR=0.46, 95 per cent CI: 0.21-0.98) and whether the COX-1 staining distribution was patchy rather than diffuse (HR=0.25, 95 per cent CI: 0.08-0.014). CLINICAL SIGNIFICANCE: This study suggests that although the prognosis for inoperable FOSCC remains poor, palliative treatments may offer a survival advantage that compares favourably with more aggressive treatment methods. Further work is needed to evaluate NSAID therapy in this disease, in particular to determine whether the potential survival advantage is because of an analgesic or anticancer effect or both. COX-1 distribution patterns may have a role as a prognostic indicator in this disease.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17559521/